Study of a new drug for diffuse large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with diffuse large B-cell lymphoma.
- Your lymphoma has returned or not responded after at least 2 prior treatments (but no more than 5).
- Your cancer is measurable on scans or tests.
- You are not pregnant or breastfeeding.
- You have not had a stem cell or organ transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies selinexor added to standard R-CHOP chemotherapy in people with a high-risk type of diffuse large B-cell lymphoma (DLBCL) that is “germinal center B-cell” (GC). It aims to improve disease control in people who need stronger treatment at the start.
This trial combines glofitamab and selinexor to treat diffuse large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if this two-drug combination works better than standard options.
This trial tests a new combination: selinexor (a pill that targets cancer cells) plus a standard chemotherapy regimen (R-GDP) for people with relapsed or refractory DLBCL that has a specific genetic change in the TP53 gene. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Recurrent and Refractory Diffuse Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.